Business
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor
About this update from Pharvaris N.v.
[{"type":"text","content":"ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA), to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas, to be held from March 15-17, 2024, in Panama City, Panama. Details of the presentations are as follows: 3rd ITACA National Congress, Milan, Italy, March 14-16, 2024. Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema AttacksPresenter: Mauro Cancian, M.D., Ph.D.Format: Poster PresentationDate, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 TrialPresenter: Giuseppe Spadaro, M.D., Ph.D.Format: Poster PresentationDate, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)Title: Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary AngioedemaPresenter: Andrea Zanichelli, M.D., Ph.D.Format: Poster PresentationDate, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)Title: Need for Caregiver Support for People Living With Hereditary Angioedema in European CountriesPresenter: Andrea Zanichelli, M.D., Ph.D.Format: Poster PresentationDate, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 TrialPresenter: Mauro Cancian, M.D., Ph.D. Format: Selected Oral and Poster PresentationDate, time: Saturday, March 16, 10:00 a.m. CET (5:00 a.m. EDT) 2024 HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024. Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: R...